

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/506,579
		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
(37 C.F.R. § 1.98(b))		IDS Filed	April 16, 2010

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5,518,735	May 21, 1996	Stürzebecher et al.
	5,786,328	Jul. 28, 1998	Dennis et al.
	5,602,253	Feb. 11, 1997	Antonsson et al.
	5,705,487	Jan. 06, 1998	Schacht et al.
	5,707,966	Jan. 13, 1998	Schacht et al.
	5,710,130	Jan. 20, 1998	Schacht et al.
	5,726,159	Mar. 10, 1998	Schacht et al.
	5,863,929	Jan. 26, 1999	Klimkowski et al.
	5,914,319	Jun. 22, 1999	Schacht et al.
	6,030,972	Feb. 29, 2000	Böhm et al.
	6,472,393	Oct. 29, 2002	Aliagas-Martin et al.
	6,624,169	Sep. 23, 2003	Wilhelm et al.
	6,680,320	Jan. 20, 2004	Wilhelm et al.
	6,831,196	Dec. 14, 2004	Stürzebecher et al.
	6,841,701	Jan. 11, 2005	Stürzebecher et al.
	6,841,702	Jan. 11, 2005	Magdolen et al.
	7,038,074	May 2, 2006	Moroder et al.
	7,049,460	May 23, 2006	Magdolen et al.
	7,208,521	Apr. 24, 2007	Magdolen et al.
	7,342,018	Mar. 11, 2008	Wilhelm et al.
	7,407,982	Aug. 5, 2009	Steinmetzer et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
		Serial No.	10/506,579
		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
		IDS Filed	April 16, 2010

U.S. PATENT DOCUMENTS			
	7,538,216	May 26, 2009	Sperl
	7,608,623	Oct. 27, 2009	Sperl et al.
	2004/0087511	May 6, 2004	Shiraishi et al.
	2004/0266766	Dec. 30, 2004	Sperl
	2005/0119190	Jun. 2, 2005	Stürzebecher et al.
	2006/0068457	Mar. 30, 2006	Ziegler et al.
	2006/0148901	Jul. 6, 2006	Stürzebecher et al.
	2007/0055065	Mar. 8, 2007	Stürzebecher et al.
	2007/0066539	Mar. 22, 2007	Stürzebecher et al.
	2008/0261998	Oct. 23, 2008	Sperl et al.
	2009/0117185	May 7, 2009	Steinmetzer et al.
	2010/0022781	Jan. 28, 2010	Steinmetzer et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	CA 2412181	Dec. 9, 2002	Canada	
	CH 689 611	Jul. 15, 1999	Switzerland	Abstract
	DE 100 29 015	Dec. 20, 2001	Germany	Abstract
	DE 102 10 590	Mar. 11, 2002	Germany	Abstract
	DE 102 12 555	Sep. 25, 2003	Germany	Abstract
	DE 103 01 300	Jul. 29, 2004	Germany	Abstract
	DE 42 43 858	Jun. 30, 1994	Germany	Abstract

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/506,579
		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
(37 C.F.R. § 1.98(b))		IDS Filed	April 16, 2010

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	EP 0 669 317	Aug. 30, 1995	EPO	
	EP 0 672 658	Sep. 20, 1995	EPO	
	EP 1 364 960	Nov. 26, 2003	EPO	
	WO 92/08709	May 29, 1992	WIPO	Abstract
	WO 94/18185	Aug. 18, 1994	WIPO	Abstract
	WO 94/29336	Dec. 22, 1994	WIPO	
	WO 95/29189	Nov. 02, 1995	WIPO	
	WO 96/25426	Aug. 22, 1996	WIPO	Abstract
	WO 97/23499	Jul. 3, 1997	WIPO	
	WO 00/04954	Feb. 3, 2000	WIPO	Abstract
	WO 00/14110	Mar. 16, 2000	WIPO	
	WO 00/17158	Mar. 30, 2000	WIPO	Abstract
	WO 00/58346	Oct. 5, 2000	WIPO	Abstract
	WO 00/64470	Nov. 2, 2000	WIPO	
	WO 01/96366	Dec. 20, 2001	WIPO	Abstract
	WO 01/97794	Dec. 27, 2001	WIPO	Abstract
	WO 02/06280	Jan. 24, 2002	WIPO	
	WO 02/20475	Mar. 14, 2002	WIPO	
	WO 02/50056	Jun. 27, 2002	WIPO	
	WO 03/70229	Aug. 28, 2003	WIPO	Abstract
	WO 04/062657	Jul. 29, 2004	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/506,579
		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
(37 C.F.R. § 1.98(b))		IDS Filed	April 16, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Akers, "Excipient-Drug Interactions in Parenteral Formulations," <i>J. Pharm. Sci.</i> 91(11):2283-2300 (2002).
	Asghar et al., "Human Plasma Kalikreins and Their Inhibition by Amidino Compounds," <i>Biochim. Biophys. Acta</i> 438:250-264 (1976).
	Bauer, "Hilfsstoffe," in <i>Pharmazeutische Technologie</i> . Sucker et al. (eds.), Georg Thieme Verlag Stuttgart: New York, p. 174-216 (1991).
	Bookser et al., "Syntheses of Quadruply Two-and Three-Atom, Aza-Bridged, Cofacial Bis (5,10,15,20-Tetraphenylporphyrins)," <i>J. Am. Chem. Soc.</i> 113:4208-4218 (1991).
	Choi-Sledeski et al., "Discovery of an Orally Efficacious Inhibitor of Coagulation Factor Xa Which Incorporates a Neutral P <sub>1</sub> Ligand," <i>J. Med. Chem.</i> 46:681-684 (2003).
	Collen et al., "In Vivo Studies of a Synthetic Inhibitor of Thrombin," <i>J. Lab. Clin. Med.</i> 99:76-83 (1982).
	Coussens et al., "Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations," <i>Science</i> 295:2387-2392 (2002).
	Dexter et al., "N,N-Dimethylformamide-Induced Alteration of Cell Culture Characteristics and Loss of Tumorigenicity in Cultured Human Colon Carcinoma Cells," <i>Cancer Res.</i> 39:1020-1025 (1979).
	Enyedy et al., "Structure-Based Approach for the Discovery of Bis-benzamides as Novel Inhibitors of Matrilysin," <i>J. Med. Chem.</i> 44:1349-1355 (2001).
	Eriksson et al., "The Direct Thrombin Inhibitor Melagatran Followed by Oral Ximelagatran Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Total Hip or Knee Replacement: the EXPRESS study," <i>Journal of Thrombosis and Haemostasis</i> , 1:2490-2496 (2003).
	Fareed et al., "Inhibition of Serine Proteases by Low Molecular Weight Peptides and Their Derivatives", <i>Ann. N. Y. Acad. Sci.</i> 370:765-784 (1981).
	Francis et al., "Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement," <i>N. Engl. J. Med.</i> 349:1703-1712 (2003).
	Frérot et al., "PyBOP® and PyBroP: Two reagents for the Difficult Coupling of the $\alpha,\alpha$ -Dialkyl Amino Acid, Alb," <i>Tetrahedron</i> , 47(2):259-270 (1991).
	Friedrich et al., "Catalytic Domain Structures of MT-SP1/Matrilysin, a Matrix-degrading Transmembrane Serine Proteinase," <i>J. Biol. Chem.</i> 277:2160-2168 (2002).
	Garrett et al., "Synthesis of Potent and Selective Inhibitors of Human Plasma Kalikrein," <i>Bioorg. Med. Chem. Lett.</i> 9:301-306 (1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
		Serial No.	10/506,579
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
(37 C.F.R. § 1.98(b))		IDS Filed	April 16, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Garrett et al., "Peptide Aldehyde Inhibitors of the Kallikreins: An Investigation of Subsite Interactions with Tripeptides Containing Structural Variations at the Amino Terminus," <i>J. Pept. Res.</i> 52:60-71 (1998).
	Griffin, "Role of Surface in Surface-Dependent Activation of Hageman Factor (Blood Coagulation Factor XII)", <i>Proc. Natl. Acad. Sci. USA</i> 75:1998-2002 (1978).
	Gustafsson et al., "Effects of Melagatran, a New Low-Molecular-Weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes," <i>Thromb. Haemost.</i> 79:110-118 (1998).
	Gustafsson et al., "Effects of Inogatran, A New Low-Molecular-Weight Thrombin Inhibitor, in Rat Models of Venous and Arterial Thrombosis, Thrombolysis and Bleeding Time," <i>Blood Coagulation and Fibrinolysis</i> 7:69-79 (1996).
	Gustafsson et al., "The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 367/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects," <i>Thromb. Res.</i> 101:171-181 (2001).
	Gustafsson et al., "A New Oral Anticoagulant: The 50-Year Challenge," <i>Nature Reviews Drug Discovery</i> 3:649-659, 2004.
	Hara et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa," <i>Thromb. Haemost.</i> 71:314-319 (1994).
	Herbert et al., "DX 9065a, a Novel, Synthetic, Selective and Orally Active Inhibitor of Factor Xa: In Vitro and In Vivo Studies," <i>J. Pharmacol. Exp. Ther.</i> 276:1030-1038 (1996).
	Ho et al., "Exploratory Solid-Phase Synthesis of Factor Xa Inhibitors: Discovery and Application of P <sub>3</sub> -Heterocyclic Amides as Novel Types of Non-Basic Arginine Surrogates," <i>Bioorg. Med. Chem. Lett.</i> 9:3459-3464 (1999).
	Hooper et al., "Type II Transmembrane Serine Proteases," <i>J. Biol. Chem.</i> 276:857-860 (2001).
	Ihara et al., "Prometastatic Effect of N-Acetylglucosaminyltransferase V Is Due to Modification and Stabilization of Active Matrilysin by Adding $\beta$ 1-6 GlcNAc Branching," <i>J. Biol. Chem.</i> 277:16960-16967 (2002).
	Isobe, "Inhibitory Effect of Gabexate (FOY) on Contact System," <i>Blood &amp; Vessel</i> 12:135-138 (1981).
	Kang et al., "Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matrilysin, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer," <i>Cancer Res.</i> 63:1101-1105 (2003).
	Kaplan, "Initiation of the Intrinsic Coagulation and Fibrinolytic Pathways of Man: The Role of Surfaces, Hageman Factor, Prekallikrein, High Molecular Weight Kininogen, and Factor XI," <i>Prog. Hemostasis Thromb.</i> 4:127-175 (1978).
	Kettner et al., "The Selective Inhibition of Thrombin by Peptides of Boroarginine," <i>J. Biol. Chem.</i> 265, 18289-18297 (1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
		Serial No.	10/506,579
		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
		IDS Filed	April 16, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Kettner et al., "The Selective Affinity Labeling of Factor X <sub>a</sub> by Peptides of Arginine Chloromethyl Ketone," <i>Thromb. Res.</i> 22:645-652 (1981).
	Kim et al., "Preparation of Argatroban Analog Thrombin Inhibitors with Reduced Basic Guanidine Moiety, and Studies of Their Cell Permeability and Antithrombotic Activities," <i>Med. Chem. Res.</i> 377-383 (1996).
	Kirk, "4-Lithio-1-Tritylimidazole as a Synthetic Intermediate. Synthesis of Imidazole-4-Carboxaldehyde," <i>J. Heterocyclic Chem.</i> 22:57-59 (1985).
	Lawson et al., "Studies on the Inhibition of Human Thrombin: Effects of Plasma and Plasma Constituents," <i>Folia Haematol., Leipzig</i> 109, 52-60 (1982).
	Leadley, "Coagulation Factor Xa Inhibition: Biological Background and Rationale," <i>Curr. Topics in Med. Chem.</i> , 1: 151-159 (2001).
	Lee et al., "Noncovalent Tripeptidic Thrombin Inhibitors Incorporating Amidrazone, Amine and Amidine Functions at P1," <i>Bioorg. Med. Chem. Lett.</i> 12:1017-1022 (2002).
	Lee et al., "Noncovalent Thrombin Inhibitors Incorporating an Imidazolylethynyl P1," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10:2775-2778 (2000).
	Lee et al., "Activation of Hepatocyte Growth Factor and Urokinase/Plasminogen Activator by Matriptase, an Epithelial Membrane Serine Protease," <i>J. Biol. Chem.</i> 275:36720-36725 (2000).
	Lin et al., "Characterization of a Novel, Membrane-bound, 80-kDa Matrix-degrading Protease from Human Breast Cancer Cells," <i>J. Biol. Chem.</i> 272:9147-9152 (1997).
	Lin et al., "Molecular Cloning of cDNA for Matriptase, a Matrix-degrading Serine Protease with Trypsin-like Activity," <i>J. Biol. Chem.</i> 274:18231-18236 (1999).
	Lin et al., "Purification and Characterization of a Complex Containing Matriptase and a Kunitz-type Serine Protease Inhibitor from Human Milk," <i>J. Biol. Chem.</i> 274:18237-18242 (1999).
	Long et al., "Synthesis and Evaluation of the Sunflower Derived Trypsin Inhibitor as a Potent Inhibitor of the Type II Transmembrane Serine Protease, Matriptase," <i>Bioorg. Med. Chem. Lett.</i> 11:2515-2519 (2001).
	Maduskuie et al., "Rational Design and Synthesis of Novel, Potent Bis-Phenylamidine Carboxylate Factor Xa Inhibitors," <i>J. Med. Chem.</i> 41:53-62 (1998).
	Maignan et al., "The Use of 3D Structural Data in the Design of Specific Factor Xa Inhibitors," <i>Curr. Topics in Med. Chem.</i> 1:161-174 (2001).
	Mohan et al., "Solid-Phase Synthesis of N-Substituted Amidinophenoxy Pyridines as Factor Xa Inhibitors," <i>Bioorg. Med. Chem. Lett.</i> 8:1877-1882 (1998).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/506,579
		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
(37 C.F.R. § 1.98(b))		IDS Filed	April 16, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Morrisette et al., "Low Molecular Weight Thrombin Inhibitors With Excellent Potency, Metabolic Stability, and Oral Bioavailability," <i>Bioorganic &amp; Med. Chem. Letters</i> , 14:4161-4164 (2004).
	Muramatsu et al., "Inhibitory Effects of ω-Amino Acid Esters on Trypsin, Plasmin, Plasma Kallikrein and Thrombin," <i>Biochim. Biophys. Acta</i> 242:203-208 (1971).
	Muramatsu et al., "Inhibitory Effects of ω-Guanidino Acid Esters on Trypsin, Plasmin, Plasma Kallikrein and Thrombin," <i>Biochim. Biophys. Acta</i> 268:221-224 (1972).
	Muramatsu et al., "Inhibitory Effects of Aryl <i>trans</i> -4 (Aminomethyl) Cyclohexanecarboxylate on Serine Proteases, and their Antiallergic Effects," <i>Hoppe-Seyler's Z. Physiol. Chem.</i> 363:203-211 (1982).
	Nar et al., "Structural Basis for Inhibition Promiscuity of Dual Specific Thrombin and Factor Xa Blood Coagulation Inhibitors," <i>Structure</i> , 9:29-37 (2001).
	Nelson et al., "Stereoselective Synthesis of a Potent Thrombin Inhibitor by a Novel P2-P3 Lactone Ring Opening," <i>J. Org. Chem.</i> 69:3620-3627 (2004).
	Oberst et al., "Expression of the Serine Protease Matrilysin and Its Inhibitor HAI-1 in Epithelial Ovarian Cancer: Correlation with Clinical Outcome and Tumor Clinicopathological Parameters," <i>Clin. Cancer Res.</i> 8:1101-1107 (2002).
	Ohno et al., "FOY: [Ethyl-(6-Guanidino)hexanoxy] Benzoate] Methanesulfonate as a Serine Proteinase Inhibitor. I. Inhibition of Thrombin and Factor Xa in Vitro," <i>Thromb. Res.</i> 19:579-588 (1980).
	Okada et al., "Development of Plasmin and Plasma Kallikrein Selective Inhibitors and their Effect on M1 (Melanoma) and HT29 Cell Lines," <i>Bioorg. Med. Chem. Lett.</i> 10:2217-2221 (2000).
	Okada et al., "Development of Plasma Kallikrein Selective Inhibitors," <i>Biopolymers</i> 51:41-50 (1999).
	Okamoto et al., "Recent Studies of the Synthetic Selective Inhibitors; With Special Reference to Non-Plasmin Fibrinolytic Enzyme, Plasmin and Plasma-Kallikrein," <i>Thromb. Res., Suppl. I</i> , 131-141 (1988).
	Ostrem et al., "Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry," <i>Biochemistry</i> 37:1053-1059 (1998).
	Patani et al., "Biososterism: A Rational Approach in Drug Design," <i>Chem. Rev.</i> 96:3147-3176 (1996), pages 3147-3148 and 3170.
	Pauls et al., "The Design of Competitive, Small-Molecule Inhibitors of Coagulation Factor Xa," <i>Frontiers in Med. Chem.</i> , 1:129-152 (2004).
	Perzborn et al., "In Vitro and In Vivo Studies of the Novel Antithrombotic Agent BAY 59-7939—an Oral, direct Factor Xa Inhibitor," <i>J. Thromb. &amp; Haemost.</i> 3:514-521 (2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
		Serial No.	10/506,579
		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
		IDS Filed	April 16, 2010

(37 C.F.R. § 1.98(b))

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Phillips et al., "Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): A Potent, Selective, and Orally Active Inhibitor of the Blood Coagulation Enzyme Factor Xa," <i>J. Med. Chem.</i> 41:3557-3562 (1998).
	Quan et al., "Bisbenzamidine Isoxazoline Derivatives as Factor Xa Inhibitors," <i>Bioorg. Med. Chem. Lett.</i> 7:2813-2818 (1997).
	Quan et al., "Discovery of 1-[3'-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor," <i>J. Med. Chem.</i> 48:1729-1744 (2005).
	Quan et al., "The Race to Orally Active Factor Xa Inhibitor: Recent Advances," <i>Curr. Opin. In Drug Discovery &amp; Development</i> , 7:460-469 (2004).
	Ratnoff, "Studies on the Inhibition of Ellagic Acid-Activated Hageman Factor (factor XII) and Hageman factor fragments," <i>Blood</i> 57:55-58 (1981).
	Renatus et al., "Structural and Functional Analyses of Benzamidine-based Inhibitors in Complex with Trypsin: Implications for the Inhibition of Factor Xa, tPA, and Urokinase." <i>J. Med. Chem.</i> 41:5445-5456 (1998).
	Rittle et al., "Unexpected Enhancement of Thrombin Inhibitor Potency with o-Aminoalkylbenzylamides in the P1 Position," <i>Bioorg. Med. Chem. Lett.</i> 13:3477-3482 (2003).
	Robinson et al., "Chapter 9. Anticoagulants: Inhibitors of the Factor VIIa/Tissue Factor Pathway," <i>Ann. Rep. Med. Chem.</i> 37:85-94 (2002).
	Rubini et al., "Synthesis of Isosteric Methylene-oxy Pseudopeptide Analogues as Novel Amide Bond Surrogate Units," <i>Tetrahedron</i> 43(21):6039-6045 (1986).
	Sato et al., "Antithrombotic Effects of YM-60828, a Newly Synthesized Factor Xa Inhibitor, in Rat Thrombosis Models and Its Effects on Bleeding Time," <i>Br. J. Pharmacol.</i> 123:92-96 (1998).
	Sato et al., "YM-60828, a Novel Factor Xa Inhibitor: Separation of Its Antithrombotic Effects from Its Prolongation of Bleeding Time," <i>Eur. J. Pharmacol.</i> 339:141-146 (1997).
	Satoh et al., "Medicinal Chemical Studies on Synthetic Protease Inhibitors, trans-4-Guanidinomethylcyclohexanecarboxylic Acid Aryl Esters," <i>Chem. Pharm. Bull.</i> 33:647-654 (1985).
	Shi et al., "Identification and Characterization of a Novel Matrix-degrading Protease from Hormone-dependent Human Breast Cancer Cells," <i>Cancer Res.</i> 53:1409-1415 (1993).
	Silverberg et al., "Enzymatic Activities of Activated and Zymogen Forms of Human Hageman Factor (Factor XII)," <i>Blood</i> 60:64-70 (1982).
	Soll et al., "Amidinohydrazones as Guanidine Bioisosteres: Application to a New Class of Potent, Selective and Orally Bioavailable, Non-Amide-Based Small Molecule Thrombin Inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 10:1-4 (2000).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
		Serial No.	10/506,579
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
(37 C.F.R. § 1.98(b))		IDS Filed	April 16, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Sperl et al., "Urethanyl-3-Amidinophenylalanine Derivatives as Inhibitors of Factor Xa. X-Ray Crystal Structure of a Trypsin/Inhibitor Complex and Modeling Studies," <i>Biol. Chem.</i> 381:321-329 (2000).
	Stauffer et al., "9-Hydroxyazaflorenes and Their Use in Thrombin Inhibitors," <i>J. Med. Chem.</i> , 48: 2282-2293 (2005).
	Stürzebecher et al., "Novel Plasma Kallikrein Inhibitors of the Benzamidine Type," <i>Brazilian Journal Med. Biol. Res.</i> 27:1929-1934 (1994).
	Stürzebecher et al., "Synthesis and Structure-Activity Relationships of Potent Thrombin Inhibitors: Piperazines of 3-Amidinophenylalanine," <i>J. Med. Chem.</i> 40:3091-3099 (1997).
	Stürzebecher et al., "Synthetic Inhibitors of Bovine Factor Xa and Thrombin Comparison of Their Anticoagulant Efficiency," <i>Thromb. Res.</i> 54:245-252 (1989).
	Stürzebecher et al., <i>Zentralbl. Pharm. Pharmacother. Lab. Diagn.</i> 122:240-241 (1983).
	Tada et al., "Isolation of Plasma Kallikrein by High Efficiency Affinity Chromatography and Its Characterization," <i>Biol. Pharm. Bull.</i> 24:520-524 (2001).
	Takeuchi et al., "Reverse Biochemistry: Use of Macromolecular Protease Inhibitors to Dissect Complex Biological Processes and Identify a Membrane-type Serine Protease in Epithelial Cancer and Normal Tissue," <i>Proc. Natl. Acad. Sci. USA</i> 96:11054-11061 (1999).
	Takeuchi et al., "Cellular Localization of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator as Substrates," <i>J. Biol. Chem.</i> 275:26333-26342 (2000).
	Teno et al., "Development of Selective Inhibitors against Plasma Kallikrein," <i>Chem. Pharm. Bull.</i> 39:2930-2936 (1991).
	Tucker et al., "Potent Noncovalent Thrombin Inhibitors That Utilize the Unique Amino Acid 4-Dicyclohexylalanine in the P3 Position. Implications on Oral Bioavailability and Antithrombotic Efficacy," <i>J. Med. Chem.</i> 40:1565-1569 (1997).
	Tucker et al., "Synthesis of a Series of Potent and Orally Bioavailable Thrombin Inhibitors That Utilize 3,3-Disubstituted Propionic Acid Derivatives in the P <sub>3</sub> Position," <i>J. Med. Chem.</i> 40:3687-3693 (1997).
	Tsuda et al., "Structure-Inhibitory Activity Relationship of Plasmin and Plasma Kallikrein Inhibitors," <i>Chem. Pharm. Bull.</i> 49:1457-1463 (2001).
	von der Saal et al., "Derivatives of 4-Amino-Pyridine as Selective Thrombin Inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 7:1283-1288 (1997).
	Wagner et al., "Synthese von N-[Amidinobenzyl]-und N-[Amidinophenyl]-Phthalimide und-1-Oxoisoindoline," <i>Pharmazie</i> 32:76-79 (1977).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/097001
		Serial No.	10/506,579
		Applicant	Stürzebecher et al.
		Filing Date	April 13, 2005
		Group	1621
		IDS Filed	April 16, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Weitz, "New Anticoagulants for Treatment of Venous Thromboembolism," <i>Circulation</i> , 110:1-19-1-26 (2004).
	Wikström et al., "Development and Validation of a Chiral Capillary Electrophoresis Method for Melagatran and Ximelagatran Drug Substances," <i>J. Sep. Sci.</i> 25:1167-1174 (2002).
	Zeslowska et al., "Crystals of the Urokinase Type Plasminogen Activator Variant $\beta$ -uPA in Complex with Small Molecule Inhibitors Open the Way Towards Structure-based Drug Design," <i>J. Mol. Biol.</i> 301:465-475 (2000).
	Zhang et al., "Assignment of Human Putative Tumor Suppressor Genes ST13 (alias SNC6) and ST14 (alias SNC19) to Human Chromosome Bands 22q13 and 11q24-q25 by In Situ Hybridization," <i>Cytogenet. Cell Genet.</i> 83:56-57 (1998).
	Zhu et al., "Recent Advances in Inhibitors of Factor Xa in the Prothrombinase Complex," <i>Curr. Opin. Cardiovasc. Pulmon. Renal Invest. Drugs</i> 1:63-87 (1999).
	Office Action pertaining to U.S. Patent Application No. 10/297,557 mailed November 4, 2003.
	Office Action pertaining to U.S. Patent Application No. 10/311,364 mailed November 19, 2003.
	Office Action pertaining to U.S. Patent Application No. 10/311,364 mailed April 1, 2004.
	Office Action pertaining to U.S. Patent Application No. 10/540,958, mailed November 17, 2008.
	Office Action pertaining to U.S. Patent Application No. 10/540,958, mailed June 11, 2009.
	Office Action pertaining to U.S. Patent Application No. 10/555,821, mailed January 21, 2009.
	Office Action pertaining to U.S. Patent Application No. 10/571,026, mailed December 13, 2007.
	Office Action pertaining to U.S. Patent Application No. 10/571,026, mailed February 23, 2009.
	Office Action pertaining to U.S. Patent Application No. 10/571,026, mailed October 30, 2009.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	